Iodopol/Sodium Iodide (I-131) – therapeutic capsules
About
Sodium Iodide Na131I, Hard Capsule: 37 - 7.400 MBq
Specifications
-
MI-4T
-
Radioiodide thyroid therapy is indicated in adults and children for:
Hyperthyroidism: treatment of Graves’ disease, toxic multinodular goitre or autonomous nodules
Treatment of large euthyroid (nontoxic) goitre
Reatment of papillary and follicular thyroid carcinoma, including metastatic disease.
Sodium Iodide (131I) therapy is often combined with surgical intervention and with antithyroid medicinal products.
-
One capsule contains sodium iodide (Na131I)
37 - 7.400 MBq at time of calibration.
-
37 - 7.400 MBq on calibration day
-
Monday, Tuesday & Wednesday
7 days after production
-
Hard capsule - Medium orange hard gelatin capsule, approximately 18 mm long, containing white powder.
-
Capsule contents:
Sodium carbonate
Sodium hydrogen carbonate
Sodium hydroxide
Disodium phosphate dihydrate
Sodium thiosulfate
Gelatin capsule shell composition:
Quinoline yellow (E 104)
Erythrosine (E 127)
Titanium dioxide (E 171)
Gelatin
-
21 days after production
-
≥ 95%
-
≥ 99,9%
-
The polypropylene vial placed in a shielding lead container, closed with a lead stopper which contains polypropylene insert with iodine absorber
The package contains a single capsule
Each package is accompanied by a separate polypropylene applicator for capsule administration
-
In the original package, below 25° C
